Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (July 2020)
12 slides from Little Green Pharma's investor presentation, Jul 22, 2020
Slide 1: Investor Presentation
For personal use only Investor Presentation 22 July 2020
Slide 2: Disclaimer
Disclaimer NOT AN OFFER OF SECURITIES Forward looking statement Not financial product advice For personal use only This document has been independently prepared by Little Green Pharma Ltd Certain information in this document refers to the intentions of This document does not constitute financial pro
Slide 3: Corporate Overview
Corporate Overview For personal use only Little Green Pharma Overview Top 5 Shareholders4 • Vertically integrated medicinal cannabis business with Shareholder Shareholding Ownership operations from cultivation and production through to Elixxer Ltd 30.8m 23.1% manufacturing and distribution Fleta Sol
Slide 4: Our purpose: reimagine cannabis medicine
We believe it’s necessary to produce high-quality cannabis medicines now For personal use only and develop meaningful innovative delivery systems for the future to improve patient outcomes and solve real patient problems. We are passionate about transforming lives. This drives our desire to grow and
Slide 5: Our Business Model Captures Value
Our Business Model Captures Value LGP operates across the medicinal cannabis supply chain For personal use only Cultivation & Manufacturing Product Education Distribution Production Innovation Cultivation capacity is Exclusive 5-year agreement Strong brand selling four Multiple education ~2-year tra
Slide 6: Redefining the Medicinal Cannabis Industry
Redefining the Medicinal Cannabis Industry For personal use only Generating revenue since August 2018 First Australian company to produce and export local cannabis medicines One of only a few companies globally with finished GMP1 cannabis medicines Cultivation facility capacity up to 110,000 bottles
Slide 7: Growth Strategy
Growth Strategy Little Green Pharma has existing sales and a clear pathway to increasing margins and driving significant revenue growth in domestic & international For personal use only markets 1 Proven sales in Australia 2 Clear pathway to international sales 3 Patient access and product innovation
Slide 8: Track Record of Growing Patient Access
Track Record of Growing Patient Access Strong growth in sales and patients using LGP products in Australia For personal use only 18,000 5,000 16,000 4,500 Bottles Sold (to 30 June 2020) 4,000 14,000 16,500+ Unique Paitents Using LGP Products (#) vs. 6,400+ to 31 Dec 2019 3,500 12,000 LGP Bottles Sol
Slide 9: Capability to Support Growth Strategy
Capability to Support Growth Strategy Our capability to deliver volumes extends beyond our existing cultivation footprint For personal use only Cultivation & Raw Biomass Manufacturing Capability Cultivation capacity is 110,000 bottles equivalent of cannabis oils Volume manufacturing capability w
Slide 10: News Flow – making solid progress
News Flow – making solid progress Significant commercial progress as LGP executes growth strategy For personal use only Completion of cultivation facility expansion First product delivered to Astral Health in the UK Further expansion of product line with new LGP Classic CBD 50 product First large co
Slide 11: For personal use only
> Australian medicinal aa Australian (eelalalel|eisme)its products.
Slide 12: LGP Head Office
For personal use only LGP Head Office PO Box 690, West Perth Western AUSTRALIA 6872 1300 703 999 | +61 8 6280 0050 info@littlegreenpharma.com.au 12
Little Green Pharma — Investor Presentation (July 2020) on 6ix